Distinguishing Brain Tumor Progression from Radiation Necrosis

episode

Cleveland Clinic Cancer Advances not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

🌑 Deep Space Ocean Waves | 8 Hours of Peaceful Piano with Ocean Waves & Deep Space Ambience for Healing REM Sleep 🌊 8h 56m · 20 Sep 2026 · 8 Hour Sleep Music

Commentary Box: Andrew Saville and Jason Pine discuss the Warriors finals exit, NZ Rugby's financial woes 11 min · 20 Sep 2026 · The Mike Hosking Breakfast

"It was everything we love about footy." | First Thoughts - Hawthorn vs Brisbane (21.09.26) 16 min · 20 Sep 2026 · SEN Breakfast

What does global leadership on AI look like? 11 min · 20 Sep 2026 · Consider This from NPR

Full Show Podcast: 21 September 2026 1h 30m · 20 Sep 2026 · The Mike Hosking Breakfast

MORNING TEA: Emily In Paris Comes To An End & The Channing Tatum Burner Account Chaos 8 min · 20 Sep 2026 · The Spill

Report any issue

Source

Recorded04 Feb 2021

Publisherfeeds.buzzsprout.com

Handlerec:1648343

Show notes

Samuel Chao, MD, radiation oncologist in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center of Cleveland Clinic Neurological Institute and Cleveland Clinic Cancer Center, joins the Cancer Advances podcast to talk about the work he recently presented at the American Society of Radiation Oncology (ASTRO) 2020 Annual Meeting. Listen as Dr. Chao discusses preliminary results from a recent Cleveland Clinic study that demonstrate that 18F-fluciclovine PET/CT has the potential to distinguish radiation necrosis from tumor progression in brain tumors previously treated with stereotactic radiosurgery (SRS).

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in